Microbial Limit Testing

Microbial Limit Testing for Non-Sterile Products

Microbial limit testing is the compendial framework for non-sterile products. It answers two questions: how many organisms are present, and are any of them organisms that must not be there at all. Together those form the microbiological specification for the overwhelming majority of pharmaceutical, nutraceutical and cosmetic products on the market.

DSTechnoverse performs microbial limit testing under USP <61> and <62>, Ph. Eur. 2.6.12 and 2.6.13 and the Indian Pharmacopoeia equivalents, with acceptance criteria applied from USP <1111> and Ph. Eur. 5.1.4 according to route of administration. We test oral solids and liquids, topicals, rectal and vaginal preparations, inhalation products, oromucosal formulations, herbal medicinal products, cosmetics and dietary supplements.

The part of this test that determines whether the result means anything is not the plating. It is the method suitability study, and it is the step most commonly missing when we review a client's existing programme.

The Two Halves of Microbial Limit Testing

The compendia split the work into enumeration and specified organism testing, and they are frequently confused in specifications.

• Total Aerobic Microbial Count (TAMC) — the total number of culturable aerobic bacteria, incubated on Soybean Casein Digest Agar at 30–35 °C for 3 to 5 days. Reported as CFU per gram or millilitre.
• Total Combined Yeasts and Moulds Count (TYMC) — fungal count on Sabouraud Dextrose Agar at 20–25 °C for 5 to 7 days.
• Escherichia coli — absence in 1 g or 10 g, the primary indicator of faecal contamination for oral products.
• Salmonella species — absence in 10 g or 25 g, required for materials of natural origin and most oral products.
• Pseudomonas aeruginosa — absence in 1 g, required for topical, inhalation and aqueous products.
• Staphylococcus aureus — absence in 1 g, for topical and oromucosal preparations.
• Bile-tolerant Gram-negative bacteria — quantified or qualified for products of natural origin, an indicator of poor hygiene during production.
• Candida albicans — absence in 1 g, for vaginal and certain topical preparations.
• Clostridia — absence, for specific product categories and routes.

Acceptance Criteria by Route of Administration

Limits scale with how directly the product reaches vulnerable tissue and how well it supports growth. The values below follow USP <1111> and are the criteria most commonly applied.

1. 1Non-aqueous oral preparations — TAMC 1000 CFU/g, TYMC 100 CFU/g, absence of E. coli in 1 g. The relatively permissive limits reflect low water activity, which prevents growth.
2. 2Aqueous oral preparations — TAMC 100 CFU/mL, TYMC 10 CFU/mL, absence of E. coli in 1 mL. Tighter because the water content supports proliferation during shelf life.
3. 3Rectal preparations — TAMC 1000 CFU/g, TYMC 100 CFU/g.
4. 4Oromucosal, gingival, cutaneous, nasal and auricular — TAMC 100 CFU/g, TYMC 10 CFU/g, with absence of S. aureus and P. aeruginosa in 1 g.
5. 5Vaginal preparations — TAMC 100 CFU/g, TYMC 10 CFU/g, with absence of S. aureus, P. aeruginosa and C. albicans.
6. 6Inhalation preparations — TAMC 100 CFU/g, TYMC 10 CFU/g, with absence of S. aureus, P. aeruginosa and bile-tolerant Gram-negative bacteria. The strictest non-sterile category.
7. 7Herbal medicinal products — separate and generally higher limits reflecting the agricultural origin of the material, with category-specific criteria depending on whether the product is treated with boiling water before use.

The 2x Interpretation Rule and Other Misread Details

Several details of microbial limit testing are routinely misapplied, and each of them changes whether a batch passes.

First, the interpretation factor. Compendial limits for counts are interpreted as the stated value with a 2x allowance, because plate counting has inherent variability. A TAMC limit of 1000 CFU/g is exceeded at results above 2000 CFU/g. Importantly, this applies only to counts — never to specified organism absence, which is absolute.

Second, absence is always tied to a quantity. "Absence of Salmonella" is not a specification; "absence of Salmonella in 25 g" is. A specification that omits the quantity cannot be enforced and will be challenged.

Third, TYMC counts moulds and yeasts together as a combined figure, not separately. Fourth, the enumeration limits apply to the product as it will be used, which for a product requiring reconstitution means the specification must be clear about which form it applies to.

Method Suitability: Why Most Results Are Invalid Without It

Very many pharmaceutical and cosmetic products are antimicrobial by design or by accident. Preservatives, alcohols, essential oils, high sugar or salt content, extreme pH and active ingredients with antibacterial properties all suppress the growth of organisms the test is trying to recover. A test run on such a product without neutralisation will reliably report no growth regardless of what is actually present.

Method suitability demonstrates that the method recovers a small inoculum from the actual product. It is required by the compendia for every product, and it is the single most common gap we find.

• Inoculate the prepared product with fewer than 100 CFU of the compendial organisms — S. aureus, P. aeruginosa, B. subtilis, C. albicans and A. brasiliensis.
• Recovery must fall within a factor of two of the count obtained from the same inoculum without product present.
• Where recovery fails, apply neutralisation: lecithin and polysorbate 80 for quaternary compounds and phenolics, sodium thiosulphate for chlorine and iodine, histidine for aldehydes, and beta-lactamase for penicillins.
• Where chemical neutralisation is insufficient, use membrane filtration with rinsing to physically remove the inhibitory substance from the retained organisms.
• Increasing dilution is a last resort, since it raises the limit of detection and may make the specification unverifiable.
• For specified organism tests, suitability must be demonstrated separately for each organism and each selective medium.
• Revalidate on any formulation change, preservative change, or change in the supplier of an antimicrobial ingredient.

Sample Preparation by Product Type

Sample preparation determines whether organisms present in the product ever reach the plate. Different physical forms need different handling, and applying a single generic preparation across a product range is a reliable way to under-report.

• Water-soluble solids — dissolve in pH 7.0 buffered sodium chloride peptone solution, typically a 1 in 10 dilution, with gentle mixing to avoid mechanical damage to cells.
• Non-water-soluble solids — suspend in diluent containing a wetting agent such as polysorbate 80, since hydrophobic powders otherwise float and never contact the diluent.
• Tablets and capsules — disintegrate rather than grind aggressively; excessive milling generates heat and shear that kill vegetative organisms before they can be counted.
• Oils and oily preparations — emulsify with polysorbate 80 and, where needed, warm gently to no more than 40 °C. Higher temperatures cause thermal death and a falsely low count.
• Creams and ointments — warm to no more than 45 °C with a suitable emulsifier, then dilute. The emulsion must be stable long enough for filtration or plating.
• Aerosols and pressurised products — chill and release the contents aseptically into a sterile container, accounting for propellant evaporation in the volume calculation.
• Transdermal patches — remove the release liner and extract from the whole patch surface, since the adhesive layer holds organisms that rinsing alone will not release.
• Devices and applicators supplied with a product — tested separately where they contact the product or the patient.

Herbal and Botanical Product Testing

Herbal medicinal products occupy their own place in the compendia because their microbiological reality is different. They are agricultural materials, harvested from soil, frequently dried in open air, and they arrive carrying spore formers and moulds as a matter of course rather than as a failure.

The pharmacopoeias therefore apply separate and generally higher acceptance criteria, differentiated by whether the product has boiling water added before use. A herbal tea infused with boiling water is held to a different standard from a herbal powder swallowed directly, because the preparation step itself provides a reduction.

Two risks deserve particular attention. First, high mould counts are not only a compliance issue — certain Aspergillus and Penicillium species produce aflatoxins and ochratoxin, so a fungal count in a botanical should trigger species identification and a mycotoxin risk assessment rather than a simple pass or fail. Second, botanicals frequently receive a decontamination treatment before use, and the microbiological specification must be clear about whether it applies before or after that step.

• Herbal products with boiling water added before use — TAMC up to 10⁷ CFU/g, TYMC up to 10⁵ CFU/g, with absence of Salmonella and limits on E. coli and bile-tolerant Gram-negatives.
• Herbal products used without boiling water — substantially tighter, typically TAMC 10⁵ CFU/g and TYMC 10⁴ CFU/g.
• Species-level identification of moulds where counts are elevated, to distinguish toxigenic species from benign environmental ones.
• Aflatoxin and ochratoxin A testing as a companion to fungal enumeration for high-risk botanicals.
• Specification stated explicitly as pre- or post-decontamination, since the two differ by orders of magnitude.
• Validation that any decontamination step achieves the claimed reduction on the actual material rather than on a surrogate.

Objectionable Organisms Beyond the Compendial List

The compendial specified organisms are a baseline, not a complete hazard assessment. Regulators increasingly expect manufacturers to define objectionable organisms for their specific product, route and patient population, and a product can be compendially compliant while containing an organism that is clearly unacceptable.

The clearest example is Burkholderia cepacia complex. It is not on the USP <62> list, but it has caused numerous recalls of aqueous non-sterile products and is now an explicit FDA concern for oral liquids, inhalation products and antiseptics. A product passing every compendial test while carrying B. cepacia is not a safe product.

• Burkholderia cepacia complex — critical for aqueous products, water systems, antiseptics and any product used by immunocompromised or cystic fibrosis patients.
• Other water-derived Gram-negatives — Ralstonia, Sphingomonas, Stenotrophomonas, frequently preservative-tolerant and capable of growth in the product.
• Organisms capable of growing in the specific formulation, regardless of pathogenicity, because proliferation during shelf life changes the product.
• Organisms that degrade the active ingredient or the preservative system, compromising efficacy rather than causing infection directly.
• Any organism inappropriate to the patient population — a neonatal, ophthalmic or immunocompromised-use product warrants a stricter definition than a general oral product.
• Spore formers in products that will be stored warm and humid, where a low count at release can become a high count at end of shelf life.

How DSTechnoverse Helps

• Specification setting — correct limits for your product category and route, with the sample quantity, method reference and limit of detection stated explicitly.
• Method suitability and neutralisation validation for each formulation, including membrane filtration approaches where chemical neutralisation is inadequate.
• Routine microbial limit testing — TAMC, TYMC and the full specified organism panel with agreed turnaround.
• Objectionable organism risk assessment — defining what must be absent from your specific product beyond the compendial list, and validating methods to detect it.
• Burkholderia cepacia complex testing for aqueous products, using appropriate selective media rather than assuming general screening will find it.
• Out-of-specification investigation with organism identification and source attribution.
• Statistical trending of release data, so a formulation drifting toward its limit is visible before it crosses.
• Regulatory documentation — validation packages and specification justifications for CDSCO, FSSAI and export dossiers.

Get Limits That Are Correct and Results That Are Valid

Send us your product specification and we will tell you whether the limits match your route of administration, whether the sample quantities are stated correctly, and whether method suitability exists for the formulation. Those three checks resolve most microbial limit problems before they become findings.

We operate from **Indore, Madhya Pradesh**, serving pharmaceutical, nutraceutical, cosmetic and food manufacturers across India. Microbial limit testing is our highest-volume service and we hold capacity for the batch release schedules our regular clients run.

Contact DSTechnoverse to discuss microbial limit testing, or see how it fits into finished product release.

Frequently Asked Questions

Guides and Resources

• Same-day sample collection for units in Pithampur, Dewas and Mandideep →